Syneron Unveils New Cutting-Edge Aesthetic Products at American Academy of Dermatology Annual Meeting, Underscoring Science and
03 Febrero 2011 - 6:01AM
PR Newswire (Canada)
YOKNEAM, Israel, Feb. 3, 2011 /CNW/ -- Breakthrough technologies
give doctors a wider range of treatment advantages across a more
diverse patient base Today Syneron Medical Ltd. (Nasdaq: ELOS),
www.syneron.com, the global leader in the medical aesthetic device
marketplace, with two distinct brands, Syneron and Candela
Corporation, www.candelalaser.com, announced that the company will
be featuring an exciting new family of aesthetic treatments at the
American Academy of Dermatology (AAD) 69th Annual Meeting taking
place in New Orleans, LA. The newly-launched products include
ePrime(TM) Energy-Based Dermal Volumizer(TM), CO2RE versatile
Fractional CO2 Resurfacing System and elure(TM) Advanced Skin
Lightening Technology(TM). Additionally, the revolutionary eMatrix®
complete Sublative Rejuvenation® system will be the subject of
several presentations at the conference, and will accompany the
company's full line of devices at booth 3515. "The top physicians
in the world continue to look to Syneron and Candela for innovative
solutions to the multitude of medical and aesthetic challenges in
improving patients' skin quality," said Louis P. Scafuri, Chief
Executive Officer of Syneron. "The newest family of products
underscores the company's commitment to science, results and trust,
and our dedication to working with our customers to develop
technologies that will give physicians greater flexibility to treat
a diverse patient base." Following are highlights of this exciting
line of products which bring forth an entirely new and diverse
range of treatment categories - from wrinkle reduction to skin
resurfacing and lightening: -- ePrime Energy-Based Dermal Volumizer
is yet another new and exciting innovation from Syneron and
Candela. The first minimally invasive aesthetic device to precisely
target and deliver measured radio frequency (RF) energy directly
into the deep dermis, ePrime is proven to result in dramatic tone
and volumetric improvements of the skin in a single treatment.
Andrea Willey, M.D., of Laser and Skin Surgery Center in
Sacramento, CA, stated, "The improvement in skin tone resulting
from increased volume and new collagen production is unique to
ePrime and a fascinating concept to bring to light." -- CO2RE
Fractional CO2 Resurfacing System is a versatile CO2 system that
offers the unique ability to treat both superficial and deep skin
layers simultaneously with precision-control over the intensity,
pattern and depth of ablation. "We've been very happy with the
results that we've seen using CO2RE," stated Brian Zelickson, MD,
of Zel Skin and Laser Specialists in Edina, MN. "It has a lot of
versatility and we find it works well for both fractionated
ablative resurfacing as well as traditional ablative resurfacing."
-- elure Advanced Skin Lightening Technology is the first and only
topical skin lightening product that improves appearance by
temporarily reducing melanin - the molecule that accumulates in the
skin to cause a darkened or uneven skin tone. Melanozyme(TM), the
novel natural enzyme found only in elure, provides the pathway for
a meaningful improvement in skin appearance, with healthier,
brighter, and younger-looking skin in as little as seven days.
Moreover, elure lightens the skin with no reports of skin
irritation. "I have been most impressed with not only the
significant clinical fading response I have observed with elure,
but also that the product could easily be incorporated into my
patients' skin care regimens without skin irritation," stated Tina
Alster, MD, founding Director of the Washington Institute of
Dermatologic Laser Surgery. -- eMatrix Sublative Rejuvenation is
the world's first RF-only technology for energy-based facial
rejuvenation, delivering high-intensity dermal impact with less
epidermal ablation with minimal patient downtime. eMatrix treats
skin texture and tone without skin color limitations. "Together,
Syneron and Candela are more market-responsive than ever before,"
continued Mr. Scafuri. "We know how to quickly innovate the safest
and most effective products to meet a variety of needs and price
points. These breakthrough technologies allow us to be ideally
positioned to maintain our global leadership and continue to help
physicians grow their practice." For conference attendees and
physicians interested in learning more about Syneron and Candela
technologies, please visit booth 3515 at the AAD Annual Meeting and
meet expert luminaries who will share clinical results. For more
information, visit www.syneron.com. About Syneron Medical Ltd.
Syneron Medical Ltd. - a company devoted to real technology, real
science and real results - is the leading global aesthetic device
company with a comprehensive product portfolio and a global
distribution footprint. The Company's technology enables physicians
to provide advanced solutions for a broad range of
medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite. The
Company sells its products under two distinct brands, Syneron and
Candela. With its innovative approach to aesthetic treatments,
Syneron has now entered into one of the largest in-demand
applications, skin lightening. Founded in 2000, the corporate,
R&D, and manufacturing headquarters for Syneron Medical Ltd.
are located in Israel. Syneron also has R&D and manufacturing
operations in the US. The company markets and services and supports
its products in 86 countries. It has offices in North America,
France, Germany, Italy, Portugal, Spain, UK, Australia, China,
Japan, and Hong Kong and distributors worldwide. Additional
information can be found at www.syneron.com. SAFE HARBOR FOR
FORWARD-LOOKING STATEMENTS Any statements contained in this
document regarding future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Further,
any statements that are not statements of historical fact
(including statements containing "believes," "anticipates,"
"plans," "expects," "may," "will," "would," "intends," "estimates"
and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors
that could cause actual results or events to differ materially from
those indicated by such forward-looking statements, including the
risk that the businesses of Syneron and Candela may not be
integrated successfully; the risk that the merger transaction with
Candela may involve unexpected costs or unexpected liabilities; the
risk that synergies from the merger transaction may not be fully
realized or may take longer to realize than expected; the risk that
disruptions from the merger transaction make it more difficult to
maintain relationships with customers, employees, or suppliers; as
well as the risks set forth in Syneron Medical Ltd.'s most recent
Annual Report on Form 20-F, and the other factors described in the
filings that Syneron Medical Ltd. makes with the SEC from time to
time. If one or more of these factors materialize, or if any
underlying assumptions prove incorrect, Syneron Medical Ltd.'s
actual results, performance or achievements may vary materially
from any future results, performance or achievements expressed or
implied by these forward-looking statements. In addition, the
statements in this document reflect the expectations and beliefs of
Syneron Medical Ltd. as of the date of this document. Syneron
Medical Ltd. anticipates that subsequent events and developments
will cause its expectations and beliefs to change. However, while
Syneron Medical Ltd. may elect to update these forward-looking
statements publicly in the future, it specifically disclaims any
obligation to do so. The forward-looking statements of Syneron
Medical Ltd. do not reflect the potential impact of any future
dispositions or strategic transactions that may be undertaken.
These forward-looking statements should not be relied upon as
representing Syneron Medical Ltd.'s views as of any date after the
date of this document. Contacts: Jane Smith* Director of Marketing
Communications, Candela Corporation Office: +1 (508) 358-7637 Ext.
247; Mobile: +1 (978) 314-1053 jane.smith@candelalaser.com Erin
Carney Senior Account Executive, Ruder Finn Office: +1 (212)
593-6358; Mobile: +1 (917) 692-9166 carneye@ruderfinn.com *Media
contact will be attending the AAD Annual Meeting and should be
contacted by email or cell phone with any media inquiries. Jane
Smith*, Director of Marketing Communications, Candela Corporation,
+1-508-358-7637 Ext. 247; Mobile: +1-978-314-1053,
jane.smith@candelalaser.com; Erin Carney, Senior Account Executive,
Ruder Finn, +1-212-593-6358; Mobile: +1-917-692-9166,
carneye@ruderfinn.com Web Site: http://www.syneron.com
Copyright
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024